gastroenter
ge
worldwid
health
problem
affect
peopl
age
name
impli
ge
character
inflamm
gastrointestin
tract
often
associ
symptom
diarrhea
nausea
vomit
abdomin
cramp
pain
ge
associ
diarrheal
diseas
remain
one
top
caus
death
world
especi
develop
countri
young
children
estim
death
toll
four
six
million
per
year
ge
also
common
diseas
lead
caus
morbid
develop
world
exampl
suggest
unit
state
usa
everyon
like
suffer
viral
ge
least
year
hospit
least
die
diseas
ge
caus
varieti
pathogen
includ
virus
bacteria
parasit
ingest
noninfecti
toxin
medic
virus
common
offend
agent
noroviru
nov
rotaviru
common
virus
caus
viral
ge
adenoviru
astroviru
coronaviru
parechoviru
also
known
caus
ge
human
nov
group
genet
divers
rna
virus
belong
genu
noroviru
calicivirida
famili
first
discov
character
prototyp
viru
norwalk
viru
nv
studi
nv
reveal
nov
nonenvelop
virus
rna
genom
surround
round
capsid
protein
shell
approxim
nm
diamet
classif
nov
howev
prove
difficult
controversi
recent
develop
molecular
biolog
tool
sinc
cultur
system
avail
grow
virus
vitro
accur
serotyp
base
neutral
possibl
instead
classif
nov
reli
crosschalleng
studi
volunt
immun
crossreact
analysi
electron
microscopi
lack
accuraci
reproduc
due
crossreact
antibodi
recent
develop
sophist
molecular
method
includ
revers
transcript
polymeras
chain
reaction
rtpcr
allow
reliabl
nov
classif
base
amino
acid
sequenc
major
capsid
protein
classif
system
nov
divid
five
genogroup
cluster
eight
cluster
genogroup
gi
gii
two
giii
one
giv
gv
tabl
within
five
genotyp
gi
giv
strain
found
infect
human
exclus
gii
found
human
pig
giii
gv
strain
anim
virus
infect
cattl
murin
speci
respect
current
strain
cluster
gii
preval
nov
human
popul
genom
nov
first
character
nv
contain
singlestrand
posit
sens
rna
kb
three
open
read
frame
orf
poli
tail
end
encod
polyprotein
process
viral
proteas
rnadepend
rna
polymeras
approxim
five
nonstructur
protein
includ
nucleosid
triphosphatas
vpg
two
structur
protein
major
minor
capsid
protein
encod
respect
structur
analysi
nov
reveal
viral
capsid
compos
dimer
icosahedr
symmetri
fold
two
domain
shell
domain
respons
initi
capsid
assembl
icosahedr
contact
protrud
domain
p
contain
two
subdomain
enhanc
stabil
capsid
provid
intermolecular
contact
dimer
addit
provid
sole
structur
shell
compon
nov
capsid
perform
function
includ
immunogen
infect
suggest
p
domain
may
contain
cellular
receptor
bind
site
viral
phenotyp
serotyp
determin
subdomain
variabl
sequenc
among
differ
nov
strain
found
protrud
outsid
capsid
surfac
suggest
respons
immun
recognit
cellular
interact
studi
nv
also
indic
protein
enhanc
express
level
stabil
viral
capsid
nov
one
lead
caus
ge
peopl
age
group
respons
viral
ge
adult
develop
new
diagnost
method
recogn
impact
virus
significantli
underestim
caus
far
outbreak
infect
previous
realiz
nov
requir
extrem
low
infecti
dose
challeng
studi
nv
suggest
probabl
infect
singl
viru
particl
approxim
among
suscept
human
popul
transmit
sever
rout
includ
fecalcontamin
food
water
direct
persontoperson
contact
indirect
exposur
droplet
contamin
object
infect
person
high
environment
stabil
nov
facilit
spread
among
human
popul
exampl
nov
stabl
wide
rang
temperatur
subzero
ph
even
resist
treatment
chlorin
mgl
ethanol
quaternari
ammonium
compound
detergentbas
cleaner
result
nov
highli
contagi
spread
rapidli
outbreak
commonli
occur
variou
social
place
set
peopl
share
common
food
water
sourc
close
physic
proxim
cruis
ship
school
militari
unit
nurs
home
daycar
center
hospit
restaur
cater
event
viral
shed
may
start
symptom
even
occur
continu
disappear
prolong
shed
period
sever
week
nov
enhanc
secondari
attack
rate
usual
result
largescal
outbreak
consequ
outbreak
often
lead
infect
thousand
peopl
closur
facil
busi
exampl
nov
identifi
one
common
pathogen
hospit
ward
closur
outbreak
nov
ge
distribut
worldwid
yearround
although
old
name
winter
vomit
diseas
impli
outbreak
winter
season
year
suggest
season
due
climat
condit
promot
closer
persontoperson
contact
favor
surviv
virus
studi
demonstr
variou
nov
strain
differ
season
outbreak
period
gii
strain
mostli
occur
winter
gi
virus
evenli
spread
year
due
rout
transmiss
young
children
elderli
nurs
home
resid
student
militari
personnel
travel
immunocompromis
peopl
particularli
vulner
nov
infect
recent
studi
indic
possibl
genet
basi
suscept
nov
infect
exampl
suscept
human
popul
found
associ
individu
abh
histoblood
type
mucos
cellexpress
carbohydr
secretor
statu
strain
bind
prefer
histoblood
group
antigen
hbga
receptor
furthermor
differ
viral
genotyp
found
specif
affin
certain
abo
hbga
gi
nov
preferenti
bind
group
antigen
gii
group
antigen
b
consequ
suggest
hbga
may
serv
put
receptor
nov
find
may
help
explain
phenomena
asymptomat
infect
certain
individu
develop
novspecif
antibodi
respons
shed
viru
display
typic
symptom
diseas
nv
infect
addit
acut
ge
chronic
nov
infect
also
document
immunocompromis
patient
life
cycl
nov
fulli
understood
due
lack
vitro
cell
cultur
system
small
anim
model
infect
howev
studi
asanaka
colleagu
demonstr
express
nv
genom
rna
abil
replic
transcrib
nv
subgenom
rna
subsequ
translat
mammalian
cell
moreov
express
found
gener
viru
particl
fill
nv
genom
rna
particular
cell
result
clearli
demonstr
abil
mammalian
cell
support
replic
nov
genom
rna
assembl
viral
rna
viru
particl
thu
failur
nov
replic
mammalian
cell
cultur
due
lack
host
factor
support
intracellular
express
nov
rna
instead
problem
may
lie
step
viral
bind
cellular
receptor
viru
entri
cell
receptor
bind
uncoat
viru
particl
releas
genom
rna
cytoplasm
ingest
viral
particl
symptom
vomit
diarrhea
usual
appear
incub
period
symptom
persist
cours
ill
h
often
accompani
nausea
abdomin
cramp
occasion
malais
chill
muscl
ach
headach
lowgrad
fever
molecular
cellular
mechan
diarrhea
vomit
induc
nov
fulli
reveal
furthermor
target
cell
human
nov
yet
conclus
identifi
howev
observ
nov
start
multipli
within
small
intestin
upon
infect
caus
histopatholog
lesion
jejunum
revers
broaden
blunt
jejun
villi
symptomat
asymptomat
individu
moreov
cytoplasm
vacuol
infiltr
uniqu
lymphocyt
popul
epithelium
also
observ
specul
chang
may
involv
blunt
villi
still
possibl
visual
nov
particl
biopsi
challeng
studi
vitro
bind
experi
suggest
viral
bind
occur
mostli
villi
level
although
novcaus
acut
ge
usual
mild
selflimit
treat
hydrat
fluid
instanc
necrot
enterocol
mortal
due
dehydr
occur
estim
nov
caus
death
young
children
develop
countri
death
us
per
year
furthermor
shear
frequenc
scale
nov
outbreak
becom
major
burden
healthcar
system
caus
tremend
econom
loss
develop
world
sinc
emerg
new
nov
variant
number
outbreak
increas
significantli
larg
epidem
occur
worldwid
almost
everi
year
result
nov
consid
emerg
pathogen
furthermor
recent
realiz
promin
caus
ge
potenti
caus
rapid
larg
water
food
possibl
airborn
outbreak
viral
particl
nov
also
classifi
class
b
biodefens
pathogen
current
effect
drug
vaccin
avail
treat
prevent
nov
infect
therefor
develop
vaccin
therapi
virus
urgent
need
variou
diagnost
method
develop
nov
serum
antibodi
nov
readili
detect
method
littl
clinic
relev
due
crossreact
antibodi
sinc
cultur
system
avail
nov
detect
viru
stool
sampl
becom
prefer
method
diagnosi
tradit
nov
infect
diagnos
detect
viru
immun
transmiss
electron
microscopi
tem
tem
offer
advantag
direct
visual
potenti
respons
viru
particl
stool
sampl
howev
disadvantag
requir
sophist
expens
equip
highli
special
technician
oper
moreov
concentr
intact
viru
particl
sampl
least
particlesml
order
detect
tem
provid
rapid
diagnost
result
individu
sampl
usual
within
h
sampl
deliveri
howev
sinc
oper
spend
substanti
amount
time
examin
specimen
tem
highthroughput
assay
rapidli
process
larg
number
sampl
tem
reli
identif
viral
particl
characterist
nov
morpholog
therefor
allow
reliabl
speciat
within
nov
genu
lower
specif
may
hinder
diagnosi
challeng
may
contribut
histor
underestim
nov
epidem
sever
enzymelink
immunosorb
assay
elisa
detect
nov
antigen
later
develop
nov
diagnosi
antigenbas
elisa
highthroughput
rel
easi
oper
rapidli
provid
diagnost
result
within
one
work
day
consequ
usual
method
choic
situat
larg
number
specimen
requir
screen
rapidli
econom
studi
shown
nov
antigendetect
elisa
high
specif
poor
sensit
like
due
antigen
divers
nov
strain
result
use
specif
detect
certain
nov
sensit
enough
applic
detect
broad
spectrum
nov
desir
employ
pool
antibodi
multipl
antigen
multival
antibodi
wider
rang
recombin
viral
antigen
howev
improv
sensit
elisa
clone
nv
genom
develop
molecular
biolog
method
rtpcr
stool
sampl
detect
viral
rna
increasingli
becom
popular
assay
nov
diagnosi
similar
elisabas
assay
rtpcr
rapid
robust
process
larg
number
sampl
simultan
result
obtain
within
work
day
howev
requir
rna
extract
fecal
sampl
need
expens
equip
skill
worker
oper
therefor
rtpcr
labor
intens
less
econom
elisa
use
primer
pair
design
either
highli
conserv
region
strainspecif
region
genom
rtpcr
versatil
offer
high
specif
compar
elisa
much
higher
sensit
high
sensit
assay
allow
detect
nov
sampl
concentr
viru
low
detect
method
includ
clinic
specimen
low
viral
load
environment
sampl
food
water
anoth
advantag
rtpcr
combin
subsequ
nucleotid
sequenc
allow
genotyp
trace
sourc
outbreak
hand
high
sensit
assay
may
produc
falseposit
result
nonspecif
amplif
potenti
sampl
crosscontamin
challeng
address
design
specif
primer
avoid
amplif
nonspecif
rna
implement
stringent
procedur
prevent
crosscontamin
sampl
due
extraordinari
sequenc
divers
among
virus
genu
singl
univers
primer
pair
detect
strain
nov
howev
sever
primer
pair
develop
detect
strain
gi
gii
robust
rtpcrbase
diagnost
method
optim
employ
faster
sensit
assay
realtim
quantit
rtpcr
aim
rapidli
detect
even
low
copi
number
nov
larg
number
stool
sampl
outbreak
studi
demonstr
taqman
base
realtim
pcr
offer
sensit
realtim
diagnosi
nov
sporad
case
outbreak
set
result
easi
interpret
avail
within
work
day
overal
tem
elisa
rtpcrbase
method
advantag
challeng
tem
allow
detect
respons
viral
agent
expens
low
throughput
contrast
elisa
high
throughput
econom
easi
use
requir
improv
sensit
rtpcr
combin
advantag
sensit
specif
enabl
molecular
epidemiolog
studi
three
method
detect
differ
compon
viru
therefor
complementari
particular
diagnost
applic
three
factor
dictat
choic
among
tem
elisa
rtpcr
includ
type
diagnosi
epidem
investig
vs
clinic
diagnosi
sensit
specif
assay
speed
robust
eas
use
assay
also
crucial
rememb
heterogen
complex
natur
stool
sampl
storag
condit
may
often
caus
chang
integr
viru
particl
andor
rna
consequ
affect
reactiv
enzymat
immunolog
assay
exampl
low
sensit
elisabas
method
result
signific
number
falseneg
sampl
use
diagnost
method
clinic
sampl
instead
use
screen
assay
clinic
diagnosi
take
advantag
speed
avail
perform
locat
close
patient
howev
high
specif
elisa
make
appropri
assay
outbreak
investig
avail
multipl
sampl
improv
reliabl
confirm
caus
outbreak
nevertheless
rtpcr
use
conjunct
elisa
clinic
diagnosi
outbreak
investig
confirm
posit
find
assess
neg
sampl
contrast
goal
diagnosi
track
pointsourc
infect
epidemiolog
studi
rtpcr
follow
dna
sequenc
method
choic
due
high
sensit
specif
tem
accept
gold
standard
diagnosi
nov
howev
compar
result
becom
avail
propos
either
rtpcr
posit
result
two
three
assay
discuss
regard
gold
standard
regardless
recommend
least
two
three
method
among
tem
elisa
rtpcr
combin
achiev
reliabl
clinic
diagnost
result
three
method
applic
epidemiolog
investig
nov
outbreak
depend
number
sampl
avail
current
specif
effect
vaccin
therapi
avail
prevent
treat
nov
gastroenter
gener
clinic
manag
includ
oral
administr
rehydr
solut
contain
essenti
electrolyt
sugar
treat
diarrhea
parenter
fluid
electrolyt
replac
may
requir
patient
signific
dehydr
symptom
toler
oral
fluid
replac
current
effort
focus
develop
effect
vaccin
possibl
attach
inhibitor
antiadhes
therapi
glycomimet
immunolog
knowledg
nov
mostli
obtain
human
challeng
studi
natur
outbreak
due
lack
small
anim
model
studi
show
infect
volunt
develop
immun
nov
challeng
howev
immun
one
strain
provid
complet
protect
challeng
heterolog
strain
symptomat
individu
could
often
reinfect
expos
nov
strain
year
later
indic
immun
seem
strain
genogroup
specif
short
live
challeng
studi
yield
conclus
result
regard
longterm
immun
may
confound
preexposur
volunt
variou
circul
nov
strain
observ
repeat
infect
adult
suggest
scarciti
longterm
immun
virus
howev
studi
show
close
genet
suscept
subject
infect
nov
challeng
support
possibl
longterm
immun
furthermor
commun
cohort
studi
indic
durat
symptom
gener
decreas
age
suggest
develop
least
partial
protect
nov
vaccin
current
avail
prevent
nov
ge
human
studi
support
feasibl
develop
vaccin
induc
protect
immun
reduc
diseas
burden
virus
lack
tissu
cultur
system
also
imped
develop
vaccin
nov
fortun
discoveri
spontan
assembl
express
viruslik
particl
vlp
morpholog
antigen
similar
nativ
virus
facilit
vaccin
develop
vlp
combin
best
trait
wholeviru
subunit
antigen
vaccin
develop
vlp
noninfecti
therefor
safer
inactiv
attenu
viru
due
lack
viral
nucleic
acid
genom
least
theori
immunogen
vlp
even
enhanc
nativ
viru
exclud
immunosuppress
viral
protein
composit
moreov
inactiv
process
unnecessari
vlp
product
consequ
unintend
epitop
modif
would
occur
ensur
vlp
immunogen
importantli
vlp
induc
potent
cellular
humor
immun
respons
without
adjuv
effect
vaccin
subunit
antigen
architectur
mimic
infecti
virus
vlp
produc
recombin
technolog
heterolog
express
system
without
requir
abil
support
viral
replic
particularli
import
nov
cultur
system
develop
support
growth
virus
particul
natur
dens
repetit
array
epitop
surfac
make
vlp
far
immunogen
subunit
vaccin
vlp
effect
induc
tcellmedi
immun
respons
interact
antigenpres
cell
apc
especi
dendrit
cell
dc
specif
vlp
mimic
natur
viral
infect
process
specif
recogn
taken
dc
subsequ
process
present
cytotox
cell
trigger
activ
prolifer
studi
demonstr
virus
correspond
vlp
particl
size
ideal
dc
macrophag
uptak
initi
antigen
process
thu
particul
natur
vlp
favor
target
relev
apc
optim
induct
tcellmedi
immun
respons
vlp
also
present
effici
b
cell
induc
strong
antibodi
respons
like
live
virus
quasicrystallin
surfac
vlp
array
repetit
epitop
present
prime
target
vertebr
b
cell
evolv
specif
recogn
recognit
trigger
crosslink
surfac
membraneassoci
immunoglobulin
ig
b
cell
lead
prolifer
migrat
helper
cell
activ
antibodi
product
secret
gener
memori
b
cell
thu
vlp
directli
activ
b
cell
much
lower
concentr
subunit
antigen
induc
high
titer
durabl
bcell
respons
absenc
adjuv
sinc
nov
enteropathogen
viru
potent
vaccin
also
induc
novspecif
gut
mucos
immun
oral
deliveri
gener
oral
deliveri
subunit
protein
vaccin
gut
immun
may
effect
due
possibl
denatur
degrad
antigen
stomach
acid
digest
enzym
poor
transport
gutassoci
lymphoid
tissu
galt
antigen
process
present
potenti
stimul
system
immun
toler
howev
vlp
compact
highli
order
structur
allow
resist
degrad
enzym
digest
tract
protein
vaccin
resembl
vlp
authent
viral
particl
may
also
present
danger
signal
overcom
percept
gut
antigen
benign
thu
prevent
develop
immun
toler
characterist
especi
true
vlp
nov
cognat
virus
natur
gastrointestin
pathogen
moreov
also
natur
recogn
effici
transport
galt
thu
challeng
oral
vaccin
deliveri
potenti
overcom
uniqu
structur
vlp
allow
elicit
potent
gut
immun
respons
inher
advantag
vlp
made
one
success
recombin
vaccin
platform
exampl
five
vlpbase
vaccin
hepat
b
viru
hbv
human
papillomaviru
hpv
commerci
licens
demonstr
excel
safeti
profil
longterm
protect
infect
human
success
potenti
evok
gut
mucos
immun
respons
upon
oral
deliveri
encourag
preclin
clinic
develop
test
vlpbase
vaccin
candid
nov
vlp
nov
first
produc
insect
cell
use
baculoviru
vector
plant
use
tobamoviru
geminiviru
vector
mammalian
cell
use
venezuelan
equin
enceph
vee
replicon
system
studi
demonstr
express
major
capsid
protein
alon
drive
selfassembl
vlp
morpholog
antigen
resembl
nativ
viru
particl
fig
vlp
gener
three
express
system
similar
structur
nov
vlp
exemplifi
vlp
nv
capsid
protein
nvcp
studi
insect
cellbaculovirusderiv
nvcp
vlp
cryoelectron
microscopi
xray
crystallographi
reveal
nv
capsid
nm
icosahedr
arrang
copi
kda
capsid
protein
organ
dimer
symmetri
dimer
form
two
ident
nvcp
monom
two
differ
dimer
configur
requir
correctli
form
complet
assembl
capsid
nativ
nv
particl
nvcp
also
fold
two
distinct
domain
vlp
domain
form
inner
core
shell
p
domain
protrud
capsid
similarli
subdomain
also
surfac
expos
region
nv
vlp
may
contain
hbga
neutral
antibodi
bind
site
determin
strain
specif
similar
vlp
nv
nov
includ
virus
demonstr
discuss
earlier
desir
nov
vaccin
elicit
gut
mucos
immun
oral
deliveri
feasibl
strategi
nvcp
vlp
induc
immun
evolutionari
select
enter
infect
allow
stabl
oralgastrointestin
environ
effici
transport
galt
antigen
process
present
consequ
variou
oral
dose
nvcp
vlp
rang
given
mice
examin
abil
elicit
system
mucos
antibodi
respons
shown
four
oral
dose
littl
nvcp
vlp
without
adjuv
trigger
serum
nvspecif
antiigg
respons
major
vlpfed
outbr
mice
system
igg
respons
observ
two
oral
dosag
highest
titer
induc
four
dose
vlp
moreov
mice
dosag
group
develop
nvspecif
intestin
iga
level
total
iga
inclus
mucos
adjuv
cholera
toxin
ct
significantli
chang
number
posit
respond
serum
igg
intestin
iga
significantli
enhanc
amplitud
serum
igg
respons
especi
higher
dose
vlp
thu
nvcp
vlp
clearli
potent
oral
immunogen
induc
system
gut
mucos
antibodi
respons
success
oral
deliveri
nvcp
vlp
encourag
explor
deliveri
altern
mucos
rout
studi
guerrero
colleagu
demonstr
intranas
deliveri
effect
oral
deliveri
provok
nvcpspecif
serum
igg
intestin
iga
respons
low
dose
vlp
exampl
deliveri
two
dose
insect
cellderiv
nvcp
vlp
presenc
mucos
adjuv
mutant
e
coli
heatliabl
toxin
elicit
antinvcp
titer
equival
two
dosag
oral
deliv
adjuv
vlp
addit
intestin
iga
fecal
sampl
strong
antinvcp
iga
respons
also
detect
vagin
wash
furthermor
mucos
iga
respons
long
last
could
detect
year
immun
data
demonstr
nvcp
vlp
potent
mucos
antigen
stimul
system
local
mucos
antibodi
respons
also
indic
abil
elicit
antibodi
respons
distal
mucosa
find
clearli
demonstr
abil
insect
cellderiv
nvcp
vlp
elicit
system
mucos
bcell
respons
potenti
neutral
nv
inhibit
infect
also
suggest
applic
carrier
heterolog
epitop
combat
sexual
transmit
infect
sti
exampl
chimer
nvcp
vlp
decor
epitop
sti
pathogen
potenti
induc
product
neutral
iga
reproduct
mucosa
vee
alphaviru
develop
replicon
vaccin
vector
express
specif
vaccin
code
sequenc
antigen
interest
clone
place
vee
structur
gene
downstream
promot
vee
replicon
cdna
drive
high
express
level
cotransfect
cdna
replicon
construct
anoth
construct
carri
vee
structur
gene
mammalian
cell
allow
recombin
viral
rna
pack
vee
viral
capsid
form
viru
replicon
particl
vrp
vee
vrp
infect
mammalian
cell
accumul
larg
amount
vaccin
protein
vee
structur
gene
provid
tran
vrp
format
part
recombin
genom
infect
cell
vee
vrp
onehit
event
produc
nvcp
vlp
gene
nv
clone
vee
replicon
cdna
express
mammalian
cell
veevrpmammalian
cellderiv
vlp
purifi
deliv
parent
mucos
rout
immunogen
addit
recombin
vrp
use
vaccin
produc
vlp
vivo
therefor
system
use
two
way
induc
immun
potenti
advantag
vrp
directli
use
infect
permiss
mammalian
host
target
cell
larg
quantiti
nvcp
vlp
assembl
antigen
present
b
cell
exampl
direct
subcutan
inocul
two
dose
infecti
unit
per
dose
recombin
nvcpvrp
footpad
mice
elicit
strong
system
igg
intestin
iga
respons
nv
vlp
well
heterotyp
respons
vlp
anoth
gi
nov
furthermor
serum
intestin
immun
respons
mice
inocul
two
dose
nvcpvrp
substanti
stronger
mice
given
two
oral
dose
either
veederiv
nvcp
vlp
multival
nov
vaccin
candid
also
produc
veevrp
system
test
mice
studi
demonstr
inocul
cocktail
three
four
vrp
express
strainspecif
vlp
mice
induc
strong
serum
antibodi
respons
inoculum
strain
also
elicit
receptorblock
heterotyp
antibodi
respons
novel
strain
moreov
coadministr
panel
eight
human
nov
vlp
cover
nov
infect
reveal
inclus
vlp
genogroup
gi
gii
vaccin
cocktail
detract
either
genogroupspecif
respons
induc
receptorblock
antibodi
intergenogroup
strain
compar
insect
cellbaculoviru
system
vee
vrp
system
cumbersom
expens
due
need
cotransfect
facil
vrp
product
howev
parenter
vee
vrp
inocul
shown
target
dc
stimul
potent
humor
cellular
immun
includ
protect
mucos
surfac
infect
furthermor
vrp
shown
possess
inher
adjuv
activ
like
due
stimul
immun
cell
singl
round
viral
rna
replic
mammalian
cell
overal
advantag
may
allow
vee
vpr
superior
system
baculoviru
system
vrp
directli
use
vaccin
induct
potenti
protect
immun
nov
even
though
nov
vlp
vrp
shown
promis
result
nov
vaccin
candid
product
system
base
insect
mammalian
cell
cultur
sever
limit
may
hamper
commerci
develop
vaccin
exampl
coproduct
baculoviru
particl
nov
vlp
baculovirusinsect
cell
system
may
creat
problem
vlp
purif
immunogen
regulatori
approv
sinc
residu
baculoviru
may
alter
overal
immunogen
nov
vlp
prepar
rais
safeti
concern
infect
remov
inactiv
cumbersom
expens
purif
process
chemic
treatment
procedur
increas
overal
product
cost
may
also
impair
qualiti
result
vlp
product
cost
veemammalian
cell
system
significantli
higher
insect
cell
cultur
addit
also
requir
heavi
capit
invest
construct
manufactur
facil
insect
mammalian
cellbas
product
system
also
share
challeng
scalabl
new
ferment
tank
facil
built
largerscal
product
challeng
may
hinder
full
realiz
healthbenefit
potenti
nov
vlp
especi
develop
world
result
plant
explor
safe
costeffect
scalabl
product
platform
nov
vlp
plant
consid
altern
protein
vaccin
product
system
produc
high
level
vaccin
protein
low
cost
biomass
product
requir
expens
invest
cell
cultur
facil
facil
duplic
scaleup
product
result
flexibl
capit
effici
plant
biomass
gener
scaleup
far
superior
current
fermentationbas
technolog
addit
plant
possess
eukaryot
process
machineri
proper
posttransl
modif
assembl
protein
low
risk
introduc
adventiti
pathogen
human
despit
potenti
advantag
earlier
product
protein
vaccin
use
stabl
transgen
plant
result
slow
low
level
target
protein
accumul
long
time
frame
sever
month
year
gener
transgen
plant
lack
strong
promot
posit
effect
random
insert
transgen
respons
problem
reduc
costsav
benefit
plant
product
system
challeng
vlp
product
speed
yield
overcom
develop
plant
virusbas
transient
plant
express
system
exampl
group
other
report
clone
highlevel
transient
express
plantderiv
vlp
achiev
quickli
week
vector
infiltr
magnicon
system
base
tobacco
mosaic
viru
tmv
rna
replicon
system
geminivir
dna
replicon
system
deriv
bean
yellow
dwarf
viru
beydv
improv
speed
yield
vlp
express
also
provid
plant
express
system
addit
advantag
versatil
produc
vlp
vaccin
nov
virus
rapid
antigen
drift
multipl
genogroup
strain
unpredict
epidem
around
world
effect
nov
vaccin
need
produc
shortest
achiev
time
frame
strain
identif
order
halt
spread
new
strain
prefer
lowcost
platform
allow
afford
vaccin
manufactur
locat
includ
develop
world
platform
base
transient
plant
express
like
address
cost
time
issu
provid
critic
versatil
allow
rapid
product
strainspecif
vaccin
control
potenti
nov
outbreak
time
manner
vlp
vaccin
produc
insect
mammalian
cell
cultur
purifi
product
requir
expens
downstream
process
cold
storag
transport
temperatur
success
induct
system
mucos
antibodi
respons
oral
deliveri
insect
cellproduc
nov
vlp
suggest
oral
immun
may
also
achiev
ingest
edibl
plant
part
contain
nov
vlp
attract
approach
may
reduc
need
costli
purif
step
may
circumv
logist
challeng
allow
implement
immun
program
region
refriger
medic
suppli
limit
approach
like
success
nov
vlp
nov
natur
infect
gastrointestin
system
therefor
resist
denatur
digest
oralgastrointestin
tract
moreov
resembl
nativ
viru
allow
effici
sampl
cell
gut
epithelium
transport
galt
antigen
process
present
thu
vlp
produc
edibl
plant
repres
novel
costeffect
approach
establish
gut
mucos
immun
oral
deliveri
vaccin
requir
defin
dosag
unit
strategi
may
face
regulatori
hurdl
commerci
develop
countri
howev
strategi
may
eventu
offer
feasibl
option
commerci
vaccin
deliveri
oral
rout
especi
consist
vlp
accumul
per
unit
plant
tissu
achiev
new
gener
express
vector
overal
current
plant
express
system
offer
advantag
far
beyond
tradit
proper
eukaryot
protein
modif
assembl
low
cost
high
scalabl
increas
safeti
exampl
allow
vlp
product
unpreced
speed
control
potenti
epidem
pandem
laboratori
investig
express
assembl
vlp
plant
success
produc
sever
nonenvelop
envelop
vlp
includ
one
base
nvcp
hbv
core
antigen
hbcag
envelop
protein
west
nile
viru
vlp
base
nvcp
one
investig
vlp
plant
success
express
mani
plant
speci
includ
tobacco
potato
nicotiana
benthamiana
tomato
lettuc
group
collabor
vaccin
protein
nvcp
first
express
transgen
tobacco
potato
plant
usual
took
sever
month
gener
select
transgen
tobacco
potato
plant
express
nvcp
express
nvcp
transgen
plant
approxim
fresh
tissu
weight
rather
low
compar
insect
mammalian
cellbas
express
system
howev
assembl
virions
icosahedr
vlp
resembl
insect
cellderiv
vlp
nativ
nv
particl
observ
transgen
tobacco
leav
potato
tuber
anoth
experi
gene
nv
codon
optim
express
transgen
tomato
plant
compar
studi
indic
vlp
yield
assembl
vari
depend
codon
usag
host
plant
speci
possibl
target
tissu
nvcp
accumul
instanc
nvcp
express
level
low
assembl
vlp
potato
tuber
least
tenfold
higher
express
effici
vlp
assembl
achiev
tomato
fruit
achiev
gut
mucos
immun
nv
four
dose
g
uncook
potato
tuber
contain
nvcp
fed
mice
day
immun
regim
induc
specif
serum
igg
intestin
iga
respons
mice
four
dose
purifi
nvcp
vlp
oral
deliv
mice
immun
regim
serum
antinv
respons
fourfold
higher
mice
fed
nvcpexpressingtub
humor
immun
respons
enhanc
higher
adjuv
ct
codeliv
perhap
enrich
assembl
vlp
purifi
sampl
respons
enhanc
humor
immun
nvcp
potato
tuber
assembl
vlp
also
possibl
nvcp
effici
releas
potato
tissu
deliv
galt
antigen
process
present
tomato
fruit
present
feasibl
plant
materi
develop
oral
nov
vaccin
palat
raw
potato
tuber
product
process
well
establish
food
industri
oral
deliveri
four
dose
g
freezedri
tomato
contain
vlp
stimul
strong
serum
antinvcp
igg
intestin
mucos
iga
respons
mice
furthermor
mice
develop
strong
system
mucos
antibodi
respons
higher
dosag
g
per
dose
transgen
tomato
use
studi
also
show
nvcp
fed
freezedri
tomato
immunogen
freezedri
potato
tuber
less
oxid
environ
uniqu
tissu
structur
tomato
fruit
may
allow
better
stabil
effici
releas
vlp
turn
better
immunogen
also
notic
ingest
nvcp
airdri
tomato
elicit
potent
serum
igg
intestin
iga
respons
nvcp
freezedri
tomato
possibl
freezedri
process
alter
assembl
statu
vlp
tomato
fruit
altern
airdri
may
result
better
vlp
stabil
preserv
architectur
vlp
tissu
structur
vlp
better
protect
digest
enzym
oralgastrointestin
tract
effici
releas
tissu
uptak
galt
overal
data
support
develop
oral
vaccin
nov
tomato
plant
major
challeng
point
nov
vlp
product
plant
slow
obtain
vlpexpress
plant
line
poor
vlp
yield
one
strategi
overcom
challeng
use
transient
express
system
base
vector
develop
plant
virus
system
transgen
integr
one
plant
genom
instead
present
plant
nucleu
transient
transcrib
later
transcript
transport
cytoplasm
transgen
protein
translat
system
focus
product
speed
yield
gain
flexibl
nuclear
gene
express
speed
express
amplif
virus
exampl
magnicon
transient
express
system
base
replicationcompet
tmv
potato
viru
x
pvx
allow
high
level
recombin
protein
product
within
day
vector
deliveri
inde
result
show
magnicon
system
allow
us
produc
fulli
assembl
nvcp
vlp
level
mgg
fresh
leaf
weight
flw
within
day
infiltr
n
benthamiana
plant
least
greater
product
transgen
tobacco
tomato
deliv
oral
rout
partial
purifi
vlp
per
dose
transient
express
plant
materi
provok
potent
balanc
system
respons
absenc
adjuv
signific
nvcpspecif
vagin
fecal
mucos
iga
respons
also
detect
immun
mice
immun
regim
moreov
signific
enhanc
nvcpspecif
immun
achiev
inclus
adjuv
ct
oral
immun
thu
destruct
viral
vectorbas
transient
express
system
enabl
us
overcom
challeng
associ
transgen
plant
system
render
robust
plant
system
nov
product
optim
transient
express
system
commerci
product
nov
vlp
vaccin
develop
anoth
robust
express
system
base
geminivir
beydv
dna
replicon
vector
commerci
avail
lettuc
two
major
advantag
transient
express
system
noncompetit
natur
beydv
dna
replicon
vector
use
commerci
produc
lettuc
contrast
magnicon
system
produc
protein
maxim
two
differ
heterosubunit
geminivir
vector
allow
product
vlp
least
five
heterosubunit
lettuc
cultiv
readili
rapidli
produc
larg
quantiti
wellestablish
commerci
greenhous
unlik
tobacco
relat
speci
nicotiana
n
benthamiana
lettuc
palat
plant
consum
raw
oral
deliveri
nov
vlp
nvcp
express
n
benthamiana
plant
beydv
replicon
vector
assembl
vlp
accumul
mgg
flw
leav
data
also
indic
beydv
replicon
system
allow
high
level
nvcp
vlp
express
assembl
lettuc
driven
magnicon
system
n
benthamiana
actual
vlp
accumul
highest
level
day
four
vector
introduct
indic
express
system
produc
similar
level
vlp
lettuc
much
shorter
time
frame
magnicon
system
tobacco
importantli
studi
one
first
demonstr
use
commerci
produc
lettuc
rapid
highlevel
product
vlp
repres
signific
mileston
eventu
commerci
product
nov
vlpbase
vaccin
would
allow
product
system
access
unlimit
quantiti
lowcost
materi
exist
commerci
sourc
coupl
almost
unlimit
natur
lettuc
product
high
effici
scalabl
beydv
replicon
vector
provid
us
new
nov
vlp
product
platform
low
cost
robust
safe
amen
largescal
manufactur
despit
success
express
nvcp
vlp
varieti
subunit
vaccin
plant
recent
improv
vaccin
product
level
transient
express
system
plantderiv
vaccin
licens
yet
human
use
lack
commerci
success
lie
sever
technic
regulatori
barrier
remain
overcom
challeng
includ
lack
scalabl
downstream
process
procedur
uncertainti
regulatori
complianc
product
process
lack
demonstr
date
plantderiv
vaccin
meet
requir
standard
regulatori
agenc
ident
puriti
potenc
safeti
immun
ingest
plant
tissu
still
present
viabl
approach
oral
deliv
plantproduc
vlp
product
regulatori
concern
necessit
develop
downstream
process
technolog
produc
purifi
vlp
vaccin
defin
unit
dosag
therefor
promis
plant
altern
vaccin
product
becom
realiti
technolog
must
abl
produc
suffici
quantiti
vlp
relev
scale
product
qualiti
meet
requir
standard
regulatori
agenc
us
food
drug
administr
fda
part
cgmp
complianc
upstream
process
biomateri
includ
relev
agrobacteria
strain
n
benthamiana
plant
line
qualifi
qm
process
start
establish
master
work
bank
tumefacien
strain
contain
nvcp
express
vector
seed
bank
wildtyp
n
benthamiana
grow
biomass
transient
express
gener
plant
materi
cgmpcompliant
product
nvcp
vlp
three
tumefacien
master
bank
contain
express
cassett
vlp
product
tmv
modul
tmv
modul
integras
magnicon
system
establish
bacteri
strain
ident
tumefacien
host
strain
associ
function
gene
vector
fulli
valid
bank
shown
genet
stabl
period
master
seed
bank
wildtyp
n
benthamiana
also
establish
experi
shown
seed
bank
germin
rate
produc
uniform
seedl
typic
n
benthamiana
morpholog
even
storag
fig
result
collect
demonstr
feasibl
establish
master
work
bank
tumefacien
strain
n
benthamiana
seed
meet
qualif
standard
ident
stabil
cgmp
product
nov
vlp
part
upstream
process
goal
optim
condit
permit
maxim
product
leaf
biomass
vlp
per
squar
meter
green
hous
space
studi
group
other
demonstr
temperatur
light
sourc
intens
plant
age
incub
time
leaf
infiltr
signific
impact
biomass
gener
vlp
accumul
exampl
n
benthamiana
grown
natur
light
produc
biomass
accumul
much
less
nvcp
vlp
plant
grown
artifici
light
fig
furthermor
leav
grown
naturallight
also
produc
solid
debri
vlp
extract
caus
problem
vlp
purif
data
also
indic
dark
cycl
optim
condit
gener
biomass
artifici
light
n
benthamiana
plant
grown
condit
sampl
variou
age
nvcp
vlp
express
found
plant
provid
optim
materi
vlp
product
alreadi
accumul
adequ
amount
biomass
produc
highest
level
vlp
fig
younger
plant
produc
insuffici
biomass
older
plant
tall
infiltr
start
produc
secondari
metabolit
complic
vlp
purif
consequ
n
benthamiana
optim
balanc
combin
need
biomass
gener
filtrat
oper
vlp
accumul
data
demonstr
optim
condit
biomass
produc
suffici
amount
purifi
nvcp
vlp
phase
clinic
trial
gener
squar
meter
green
hous
space
period
horizont
space
requir
type
product
could
significantli
reduc
vertic
stack
layer
growth
tray
vertic
method
effici
introduct
agrobacterium
leav
vacuum
infiltr
also
develop
illustr
express
gfp
nvcp
vlp
plant
infiltr
base
method
scaleup
condit
allow
effici
infiltr
vectorcarri
agrobacteria
entir
leaf
area
fig
accumul
highest
level
nvcp
vlp
leav
dpi
fig
b
moreov
yield
tempor
express
pattern
nvcp
vlp
scaleup
condit
similar
previou
smaller
benchscal
experi
result
clearli
indic
upstream
process
nv
vlp
product
plant
scalabl
scale
commerci
product
eat
unprocess
partial
process
nov
vlpcontain
plant
tissu
remain
viabl
option
vaccin
deliveri
purifi
vlp
welldefin
unit
dosag
like
first
gener
success
vaccin
candid
commerci
due
regulatori
requir
therefor
absolut
necessari
robust
scalabl
downstream
process
effect
recov
purifi
vlp
place
order
plantproduc
nov
vlp
vaccin
becom
commerci
realiti
optim
downstream
process
abl
preserv
integr
vlp
produc
highli
purifi
vlp
high
recoveri
rate
minim
number
process
step
also
scalabl
econom
compliant
fda
cgmp
regul
common
practic
nov
vlp
purif
densiti
gradient
ultracentrifug
method
use
character
vlp
size
assembl
practic
commerci
vlp
manufactur
difficult
scaleup
timeconsum
may
also
problemat
preserv
integr
vlp
hyperosmot
gradient
agent
sever
centrifug
forc
often
shear
vlp
meet
demand
scalabl
robust
method
nov
vlp
process
new
trend
start
toward
sophist
method
like
filtrat
chromatographi
exampl
group
recent
develop
robust
scalabl
downstream
process
scheme
recov
nvcp
vlp
plant
fig
threestep
process
plant
extract
process
low
ph
precipit
ultrafiltr
diafiltr
ufdf
tangenti
flow
filtrat
tff
membran
ionexchang
iex
chromatographi
show
low
ph
ufdf
elimin
plant
host
protein
iex
chromatographi
purifi
nvcp
vlp
puriti
fig
lane
product
run
variou
scale
plant
biomass
demonstr
downstream
process
highli
scalabl
consist
yield
highli
pure
nvcp
vlp
high
recoveri
rate
contrast
gradient
centrifug
labori
timeconsum
new
method
robust
scalabl
complet
within
h
instead
sever
day
importantli
new
process
fulli
cgmp
compliant
produc
cgmp
grade
vlp
human
clinic
trial
new
technolog
microarray
also
employ
optim
nov
vlp
purif
plant
exampl
lab
collabor
identifi
peptid
ligand
specif
affin
nvcp
vlp
microarray
conjug
chromatographi
bead
affin
ligand
allow
recoveri
highli
purifi
nvcp
vlp
n
benthamiana
plant
extract
approach
advantag
tradit
affin
chromatographi
affin
ligand
entir
synthet
therefor
insensit
ligand
denatur
degrad
advantag
along
rapid
ligand
discoveri
process
low
cost
peptid
product
would
allow
applic
largescal
nov
vlp
manufactur
one
remain
challeng
commerci
plantderiv
vaccin
lack
exampl
meet
requir
standard
regulatori
agenc
ident
puriti
potenc
safeti
part
effort
overcom
challeng
laboratori
identifi
develop
analyt
assay
monitor
inprocess
sampl
ensur
final
vlp
product
meet
preset
specif
releas
human
pharmaceut
ident
puriti
concentr
tertiari
structur
function
concentr
host
contamin
molecul
essenti
cgmp
complianc
tabl
analys
show
ident
assembl
final
vlp
product
confirm
puriti
concentr
appear
residu
host
dna
concentr
stabil
conform
insect
cellderiv
refer
standard
final
vlp
product
elicit
strong
nvcpspecif
system
local
distal
mucos
immun
respons
mice
demonstr
potenc
result
provid
first
exampl
plantderiv
nov
vlp
scaleup
process
meet
predetermin
releas
specif
summari
product
studi
laboratori
success
develop
upstream
process
plant
biomass
gener
infiltr
robust
nov
vlp
accumul
novel
downstream
process
effici
recov
vlp
plant
tissu
moreov
process
success
oper
cgmp
regul
produc
highqual
vlp
meet
preset
releas
specif
ident
puriti
potenc
safeti
henc
studi
provid
first
preced
academ
set
produc
plantderiv
vaccin
scale
cgmp
regul
import
step
plantproduc
nov
vlp
vaccin
becom
commerci
realiti
ongo
research
group
collabor
evalu
system
mucos
immun
cgmppurifi
vlp
codeliv
mucos
variou
adjuv
preliminari
data
suggest
mucos
immun
sever
adjuv
evok
stronger
serum
igg
mucos
iga
respons
vlp
alon
anticip
purifi
nvcp
vlp
cgmp
plant
product
run
adjuv
defin
current
studi
use
new
phase
human
clinic
trial
near
futur
success
demonstr
strong
system
mucos
immunogen
preclin
studi
led
sever
clinic
trial
exam
safeti
immunogen
nov
vlpbase
vaccin
human
tabl
insect
cellderiv
nvcp
vlp
initi
test
two
phase
trial
first
trial
antibodyposit
adult
volunt
given
two
oral
dose
day
vlp
formul
water
without
adjuv
observ
serum
igg
respons
dose
depend
vaccin
subject
receiv
vlp
increas
nv
specif
titer
least
fourfold
fifteen
particip
respond
serum
igg
titer
first
vlp
dose
show
increas
second
dose
importantli
side
effect
observ
vaccin
volunt
second
trial
safeti
immunogen
nvcp
vlp
test
adult
seroposit
healthi
individu
year
age
two
oral
dose
increas
amount
antigen
without
adjuv
use
immun
regim
signific
increas
number
nvspecif
iga
antibodysecret
cell
asc
observ
vaccin
volunt
approxim
volunt
develop
salivari
fecal
genit
fluid
iga
antibodi
increas
nvspecif
igg
titer
also
detect
particip
receiv
vlp
howev
increas
vlp
dose
increas
rate
seroconvers
igg
titer
result
first
two
trial
encourag
howev
maxim
serum
igg
titer
elicit
oral
immun
lower
experiment
nv
infect
consequ
two
addit
phase
studi
conduct
investig
whether
immunogen
nvcp
vlp
enhanc
use
mucos
adjuv
insect
cellproduc
nvcp
vlp
formul
dri
power
contain
agonist
adjuv
monophosphoryl
lipid
mpl
mucoadher
chitosan
deliv
rout
healthi
subject
studi
stepwis
dosag
escal
trial
nvcp
vlp
studi
dose
comparison
studi
two
highest
dosag
vlp
studi
indic
deliveri
nvcp
vlp
dri
power
formula
mpl
chitosan
well
toler
vaccinerel
seriou
advers
event
occur
studi
dosedepend
serum
igg
iga
respons
observ
titer
increas
respect
group
studi
group
develop
higher
titer
igg
iga
increas
respect
group
differ
signific
statist
term
vaccine
group
develop
iga
asc
furthermor
express
home
molecul
target
mucos
peripher
lymphoid
tissu
detect
asc
compar
previous
describ
oral
nonadjuv
vlp
deliveri
mpladjuv
vlp
induc
higher
number
asc
correl
protect
immun
nv
diseas
still
unknown
mucos
prime
asc
combin
serum
igg
iga
antibodi
may
contribut
protect
phase
iii
trial
initi
assess
safeti
immunogen
nvcp
vlp
administ
rout
follow
live
viru
challeng
determin
effect
approach
prevent
limit
nv
infect
human
demonstr
safeti
efficaci
plantderiv
nov
vlp
phase
clinic
trial
conduct
potatoproduc
nvcp
vlp
trial
two
three
dose
g
uncook
nvcptransgen
potato
tuber
vlp
per
dose
oral
ingest
human
subject
day
day
one
volunt
respond
rise
nvspecif
iga
asc
major
respond
follow
first
dose
four
volunt
develop
nvcpspecif
serum
igg
six
develop
specif
intestin
iga
mean
titer
rise
respect
incid
rate
nausea
vomit
mild
cramp
fever
diarrhea
similar
among
volunt
ate
recombin
control
tuber
indic
ingest
vlpproduc
potato
tuber
appear
safe
togeth
result
indic
immunogen
safeti
use
edibl
vlpcontain
plant
part
oral
vaccin
nov
human
howev
overal
antibodi
respons
strong
obtain
oral
deliv
purifi
nvcp
vlp
per
dose
produc
insect
cell
perhap
variabl
effect
vlp
dosag
due
inconsist
nvcp
content
poor
vlp
assembl
potato
tuber
may
caus
weak
antigen
potenc
plantderiv
vlp
may
also
reduc
poor
releas
potato
tissu
gut
lumen
light
result
recent
human
clinic
trial
insect
cellderiv
vlp
near
futur
plan
new
human
clinic
trial
purifi
nvcp
vlp
cgmp
run
adjuv
defin
current
studi
see
qualiti
control
section
overal
clinic
studi
demonstr
nov
vlpbase
vaccin
candid
produc
insect
cell
plant
safe
immunogen
human
sinc
model
nv
infect
human
volunt
establish
recent
efficaci
adjuv
nvcp
vlp
vaccin
oral
deliveri
examin
human
challeng
model
uncultiv
nov
capsid
proteinbas
vlp
possess
best
properti
immunogen
safeti
stabil
manufactur
vaccin
candid
prevent
nov
ge
like
vlpbase
vaccin
nov
vlp
shown
induc
potent
cellular
humor
immun
respons
without
adjuv
due
resembl
infecti
virus
sinc
nov
natur
caus
infect
gastrointestin
tract
vlp
stabl
low
ph
resist
digest
enzym
result
administ
oral
elicit
potent
mucos
antibodi
respons
system
respons
mice
human
exampl
oral
deliveri
nvcp
vlp
induc
robust
product
antinv
serum
intestin
antibodi
peripher
blood
mononuclear
cell
similarli
potent
system
mucos
immun
respons
provok
mice
human
deliveri
abil
induc
novspecif
gut
mucos
immun
mucos
deliveri
provid
vlp
distinguish
advantag
vaccin
enteropathogen
virus
moreov
safeti
nov
vlp
demonstr
sever
human
clinic
trial
stabil
nov
vlp
also
favor
commerci
vaccin
lyophil
store
simpl
buffer
mani
year
without
degrad
significantli
studi
group
other
demonstr
nov
vlp
robustli
produc
recombin
technolog
plant
larg
scale
low
cost
develop
novel
downstream
process
success
product
nvcp
vlp
meet
regulatori
releas
specif
ident
puriti
potenc
safeti
group
provid
addit
step
nov
vlp
vaccin
becom
commerci
realiti
success
demonstr
potenti
feasibl
vlp
nov
vaccin
suggest
serv
excel
model
develop
effect
strategi
mucos
immun
nonrepl
antigen
still
remain
challeng
develop
efficaci
nov
vaccin
exampl
question
whether
vlpbase
vaccin
protect
human
live
nov
challeng
still
remain
unansw
moreov
difficult
predict
level
protect
new
vaccin
candid
provid
due
lack
complet
understand
immun
correl
protect
problem
intensifi
lack
cultur
system
cultiv
nov
vitro
lack
small
anim
model
nov
pathogenesi
furthermor
lack
complet
crossprotect
among
divers
genotyp
genogroup
virus
rapid
evolut
new
variant
strain
hamper
develop
efficaci
vaccin
protect
multipl
nov
strain
overal
potent
system
mucos
immunogen
robust
lowcost
cgmp
manufactur
plant
safeti
profil
human
clinic
trial
support
develop
vlpbase
vaccin
prevent
novrel
ge
due
divers
capsid
protein
among
differ
nov
strain
rapid
antigen
drift
vaccin
develop
focu
multival
vlp
vaccin
deriv
capsid
protein
preval
strain
furthermor
vigil
epidemiolog
surveil
must
coupl
nov
vaccin
product
identifi
move
target
includ
preval
circul
strain
formul
optim
protect
new
data
ongo
plan
human
clinic
trial
particularli
challeng
trial
shed
new
light
efficaci
vlp
prevent
limit
nov
infect
next
year
may
also
provid
clue
immun
correl
protect
knowledg
facilit
develop
efficaci
nov
vaccin
linger
critic
plantbas
product
platform
absenc
approv
human
product
usa
year
activ
research
develop
excitingli
last
barrier
overcom
recent
approv
plantproduc
glucocerebrosidas
commerci
name
eleysotm
fda
treat
gaucher
diseas
herald
new
era
field
plantmad
pharmaceut
specul
plantbas
product
system
offer
superior
scalabl
safeti
time
costsav
benefit
nov
vlp
manufactur
